Bottle of Vaccine, treatment of Cancer (© Giovanni Cancemi - stock.adobe.com)
IRVINE, Calif. — In the world of cancer treatment, glioblastoma (GBM) stands out as one of the most challenging adversaries. This aggressive and deadly brain cancer, which mainly affects adults, has long been associated with grim survival rates despite advances in medical science. However, there’s now a ray of hope on the horizon thanks to next-generation vaccines.
Researchers Robert Dillman and Daniela Bota from the University of California-Irvine explain that recent developments in vaccine technology are offering new possibilities for patients battling this disease. Two promising candidates, in particular, are capturing the attention of researchers and clinicians alike: SurVaxM and AV-GBM-1. These innovative approaches represent a significant step forward in the ongoing battle against glioblastoma. The findings are published in the journal Oncotarget.
“Vaccines have been considered a promising approach for GBM for many years,” the researchers note in a media release.
Glioblastoma is a rare but lethal form of brain cancer that affects approximately 13,000 people in the United States each year. Despite aggressive treatment combining surgery, radiation, and chemotherapy, the outlook for patients has remained bleak. Most clinical trials in recent years have reported median survival times of around 16 months, with only about 25% of patients surviving for two years after diagnosis.
The search for more effective treatments has led scientists to explore the potential of cancer vaccines. Unlike traditional vaccines that prevent diseases, these therapeutic vaccines aim to stimulate the body’s immune system to fight existing cancer cells. The concept is elegantly simple: train the immune system to recognize and attack cancer cells as if they were foreign invaders.
SurVaxM, one of the promising vaccine candidates, targets a protein called survivin that is commonly found in glioblastoma cells but rarely in healthy cells. This vaccine combines the survivin protein with other components that help boost the immune response. Early results from a phase 2 trial have been encouraging, with patients showing improved survival rates compared to historical data.
The other contender, AV-GBM-1, takes a more personalized approach. This vaccine is created using the patient’s own immune cells and tumor tissue. By exposing the patient’s immune cells to their unique tumor antigens, the vaccine aims to create a tailored immune response against the cancer. Initial results from a clinical trial of AV-GBM-1 have also shown promise, with some patients experiencing longer survival times than expected.
These vaccines represent a shift in how we approach glioblastoma treatment. Instead of relying solely on therapies that directly attack cancer cells, they harness the power of the body’s own immune system to fight the disease. This approach not only has the potential to be more effective but may also lead to fewer side-effects compared to traditional treatments.
While these results are exciting, it’s important to note that the journey from promising clinical trials to widely available treatments is often long and complex. Larger, randomized trials will still be necessary to confirm the effectiveness of these vaccines and to better understand which patients are most likely to benefit. Nevertheless, the emergence of these vaccine candidates offers a glimmer of hope in a field that has seen little progress in recent decades.
Paper Summary
Methodology
The research into these new vaccine candidates involved carefully designed clinical trials. For SurVaxM, researchers selected newly diagnosed glioblastoma patients who had undergone complete tumor removal and completed initial radiation and chemotherapy. The vaccine was then administered through injections under the skin, along with additional immune-stimulating substances.
AV-GBM-1 took a different approach. Patients were enrolled before starting standard treatment. Researchers collected tumor tissue during surgery and used it to create a personalized vaccine for each patient. This vaccine was then given through injections after the patient had recovered from initial treatments.
Both studies carefully monitored patients for side effects and tracked how long they lived without the cancer progressing (progression-free survival) and overall survival time.
Key Results
The SurVaxM trial reported a median overall survival of 25.9 months from the time of diagnosis for the group of patients who received the vaccine. This is notably longer than the typical 16-month survival seen in many previous studies.
For AV-GBM-1, the median overall survival was 16.0 months from the time of enrollment in the study, with 33% of patients surviving for two years and 23% for three years. While these numbers may seem lower than SurVaxM’s results, it’s important to note that the studies had different designs and starting points for measuring survival.
Study Limitations
Both studies had limitations that are important to consider. The SurVaxM trial was relatively small and only included patients who had responded well to initial treatments, which may have skewed the results positively. The AV-GBM-1 study, while including a broader range of patients, was also small and didn’t have a control group for direct comparison.
Additionally, creating personalized vaccines like AV-GBM-1 can be challenging and time-consuming, which could limit its widespread use if approved.
Discussion & Takeaways
These studies suggest that vaccine therapy could be a valuable addition to glioblastoma treatment. The ability to stimulate the immune system against cancer cells offers a new avenue of attack against this difficult-to-treat disease.
However, the researchers emphasize that larger, randomized trials are needed to confirm these promising results. They also highlight the need to better understand which patients are most likely to benefit from these vaccines and how they might be combined with other treatments for maximum effect.
The success of these early trials has led to plans for larger studies. A randomized phase 2/3 trial for AV-GBM-1 is already in the works, which will provide more definitive evidence of its effectiveness.
Funding & Disclosures
The paper notes that one of the authors, Robert O. Dillman, is employed by Aivita Biotherapeutics, the company developing AV-GBM-1. This connection is important to disclose as it could potentially influence the interpretation of the results. The other author, Daniela A. Bota, reports no conflicts of interest. The paper itself did not receive specific funding, as it is a review of existing research rather than a new study.
